Shasqi
Mukul Agarwal has extensive experience in business leadership within the pharmaceutical and biotechnology sectors. Currently serving as the Chief Business Officer at Shasqi, Mukul previously held the roles of CFO and CBO at Foresight Diagnostics Inc., and Vice President of Corporate Development at Forty Seven Inc. Additionally, Mukul was Vice President of Business Development at Revance Therapeutics, Inc., and Senior Director of Business Development at Anacor, which was later acquired by Pfizer. Mukul holds a Master of Business Administration (M.B.A.) in Finance from Carnegie Mellon University's Tepper School of Business, and has educational credentials from The Ohio State University.
Shasqi
Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies.